VIDEO: Steroid use, loss of response prevalent in IBD care
In this exclusive video, Anita Afzali, MD, from The Ohio State University Wexner Medical Center, discusses data she presented for Digestive Disease Week from a survey that assessed patient and provider perspectives on the management of inflammatory bowel disease.
In the study, investigators found that physicians were not as concerned as patients about corticosteroid use. While 48% of patients with Crohn’s disease and 42% of patients with ulcerative colitis had concerns about any steroid use, only 27% of providers had the same concern.
Afzali said more focused education is needed for providers when it comes to steroid use in IBD and how to address the unmet need for effective, prolonged therapies.
Afzali, et al. Abstract 123. Presented at: Digestive Disease Week; May 2-5, 2020; Chicago (meeting canceled).
Disclosures: Afzali reports acting as a consultant for AbbVie, Celgene, Janssen, Takeda and UCB; and receiving speaker fees from AbbVie, Janssen, Pfizer, Takeda and UCB. Please see the study abstract for all other authors’ relevant financial disclosures.